Compare · ILMN vs PDCO
ILMN vs PDCO
Side-by-side comparison of Illumina Inc. (ILMN) and Patterson Companies Inc. (PDCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and PDCO operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $29.37B, about 10.6x PDCO ($2.76B).
- ILMN has hit the wire 3 times in the past 4 weeks while PDCO has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 7 for PDCO).
- Company
- Illumina Inc.
- Patterson Companies Inc.
- Price
- $194.06-1.49%
- $31.34+0.03%
- Market cap
- $29.37B
- $2.76B
- 1M return
- +10.86%
- -
- 1Y return
- +76.55%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 1992
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 7
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Patterson Companies Inc.
Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. It operates through three segments; Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritionals, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest PDCO
- SEC Form 15-12G filed by Patterson Companies Inc.
- SEC Form 8-K filed by Patterson Companies Inc.
- Director Tomczik Pamela J returned 7,820 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Schrimsher Neil A returned 48,788 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Mckoy Philip returned 18,114 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Frenzel Robert returned 38,242 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Feragen Jody H returned 56,145 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Buck John D returned 92,869 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Blanco Alex N returned 41,300 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Agarwal Meenu returned 12,788 shares to the company, closing all direct ownership in the company (SEC Form 4)